Abraxis BioScience (ABII)

The loss of the assets, revenue, cash flows and results of operations of Abraxis BioScience will adversely affect our financial position and operations.

Our assets, revenue, cash flows and results of operations are currently included in the consolidated financial statements of Abraxis BioScience. If the separation is completed, our assets, revenue, cash flows and results of operations will no longer be included in the consolidated financial statements of Abraxis BioScience, and our financial positions and results of operations will therefore be significantly different than they were prior to completion of the transactions and, following completion of the transactions, will have materially less assets, revenue and cash flows than Abraxis BioScience currently has on a consolidated basis. Abraxis BioScience’s diversification resulting from operating the hospital-based products business alongside the proprietary products business tends to mitigate financial and operational volatility. The separation will eliminate that diversification, and we may experience increased volatility in terms of cash flow and operating results.